Non-invasive positron emission tomography (PET) enables the measurement of metabolic and molecular processes with high sensitivity. PET plays a significant role in the diagnosis, prognosis, and treatment of brain tumors and predominantly detects brain tumors by detecting their metabolic alterations, including energy metabolism, amino acids, nucleic acids, and hypoxia. Glucose metabolic tracers are related to tumor cell energy and exhibit good sensitivity but poor specificity for malignant tumors. Amino acid metabolic tracers provide a better delineation of tumors and cellular proliferation. Nucleic acid metabolic tracers have a high sensitivity for malignant tumors and cellular proliferation. Hypoxic metabolism tracers are useful for detecting resistance to radiotherapy and chemotherapy. Therefore, PET imaging techniques are useful for detecting biopsy-targeting points, deciding on tumor resection, radiotherapy planning, monitoring therapy, and distinguishing brain tumor recurrence or progression from postradiotherapy effects. However, it is not possible to use only one PET tracer to make all clinical decisions because each tracer has both advantages and disadvantages. This study focuses on the different kinds of PET tracers and summarizes their recent applications in patients with gliomas. Combinational uses of PET tracers are expected to contribute to differential diagnosis, prognosis, treatment targeting, and monitoring therapy.
Introduction
gliomas, the most common primary brain tumors, constitute a heterogeneous group of histological subtypes, including oligodendrogliomas, astrocytomas, ependymal tumors, and choroid plexus tumors, classified according to the world Health Organization (wHO) grading criteria based on cellular alterations related to tumor aggressiveness. 1, 2) accurate tissue diagnosis of gliomas is important for appropriate treatment planning and prognosis. Final diagnosis and grading are performed by the pathological diagnosis of surgical specimens. However, some glioma cases tend to be diagnosed less stringently than by actual grading done through pathological diagnosis. Therefore, several different imaging modalities are needed for diagnosis, grading, assessment of recurrence, and treatment planning and monitoring. Diagnostic imaging of gliomas uses various methods and has recently advanced. Magnetic resonance imaging (MRi) is the most commonly used method for determining tumor size and location and can delineate secondary phenomena, but the morphological information obtained is limited for diagnostic and prognostic decisions. Unlike morphological imaging, positron emission tomography (PeT) uses radiotracers to achieve metabolic and molecular imaging and can improve diagnoses. Depending on the radiotracer, various molecular processes can be visualized. The vast majority of PeT tracers take the advantage of the increased intratumor cell proliferation. 3) in the following sections, the most important or promising PeT approaches for diagnosis, grading, treatment planning, and prognosis for gliomas are presented.
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Unlike glucose-6-phosphate, [ 18 F]FDg-6-phosphate is not a substrate of glucose-6-phosphate isomerase and does not undergo further metabolism in the glucose pathway; therefore, it is trapped inside the cells. Consequently, [ 18 F]FDg accumulation increases in highly malignant tumors. 8) [
18 F]FDg PeT is applicable for the imaging of gliomas because of increased glucose metabolism in high-grade gliomas and the positive correlation between glycolysis rate and malignancy. 9) However, because of high physiological glucose metabolism in normal brain tissue (cerebral cortex, basal ganglia, and thalamus) and inflammatory tissue (i.e., macrophages), glioma identification in such tissues is difficult. Thus, the decreased sensitivity of lesion detection of [ 18 F]FDg PeT is a major limitation for assessing gliomas. 10) Conversely, [ 18 F]FDg uptake by a typical primary central nervous system lymphoma (PCNSL) is about 2.5 times higher than that in the normal gray matter; therefore, it is useful for the differentiation and diagnosis of typical PCNSLs.
11)

Amino acid metabolism
Radiolabeled amino acids have been used as suitable PeT tracers in brain tumors, 12) which play a key role in cell proliferation. 13 17) Moreover, it has been reported that [ 11 C]MeT uptake is high in oligodendrogliomas because of their high cell density 18) and in pilocytic astrocytomas despite being a wHO grade i glioma, because of increased vascularization and the high density of transporters in its vascular endothelial cells.
3) Thus, it is difficult to diagnose gliomas using only [ 11 The maximal or mean standardized uptake values (SUVs), calculated as the tissue radioactivity concentration divided by the injected dose and patient's body weight, are the most widely used semi-quantitative parameters of radioactivity in target tissues. SUV analysis can be performed voxelwise as well as by means of regions or volumes of interest. For the exact interpretation of tumor tracer uptake, it is essential to determine whether the changes are related to radiotracer transport, metabolism, distribution and/or back-diffusion. This analysis uses dynamic PeT data acquisition and requires serial arterial blood samplings. Dynamic image acquisition (measuring the rate of accumulation of radiotracers in the brain over time) allows the modeling of regional radiotracer transport and kinase activity rates. 4) The model separates radiotracer uptake into two compartments with flux rates characterized by kinetic parameters (k 1 , k 2 , k 3 , and k 4 ), 5) but the analysis is not amenable to routine clinical use. 11 C]4DST uptake, which reflects the whole DNa synthesis process, and to be useful for PeT imaging of gliomas.
Diagnosis and Grading of Gliomas
30)
Hypoxic metabolism
Malignant tumors are characterized by hypoxic tissue (lower oxygen concentration), which results from the insufficient blood supply that occurs with aberrant tumor cell proliferation 31) and vascular occlusion of blood vessels within the tumor. 32) Hypoxia promotes neovascularization through various molecular signals, 33) may drive the peripheral growth of a tumor, and is associated with tumor progression and resistance to chemotherapy 34) and radiotherapy. 35) One of the most widely used PeT radiotracers for molecular imaging of hypoxia is
, which is a nitroimidazole derivative 36) and is exclusively trapped in hypoxic cells. 37) in cellular environments with a high partial pressure of oxygen (normoxic tissue), the radical anion is reduced back to the parent compound before further reaction. in hypoxic environments, the radical anion persists long enough to react with other electrons in the cell to form the twoelectron reduction product. This can react further with intracellular macromolecules, trapping the tracer in the hypoxic environment and providing a contrast between hypoxic and normoxic regions. 38) in our results, [ 18 F]FMiSO showed high accumulation in wHO grade iV gliomas but not in wHO grade ii and iii gliomas, and an [
18 F]FMiSO PeT study discriminated wHO grade iV gliomas from wHO grade ii and iii gliomas. 39) These results are consistent with those of recent studies in which the volume and intensity of hypoxia in wHO grade iV gliomas before radiotherapy were strongly associated with shorter time to progression and survival. 40 41) and 64 Cu-diacetyl-bis-(N-N-N-N-methylthiosemicarbazone) ([ 64 Cu]aTSM). 38) Further study of these tracers would be of valuable for the prognosis of glioma patients. Table 1 summarizes the advantages and disadvantages of the four kinds of PeT tracers. Figure 1 shows 
Representative cases
Treatment Planning Biopsy planning
Brain tumor diagnosis can be performed at the time of surgical resection or through stereotactic biopsy. Biopsy is performed to obtain a diagnosis in de novo cases when the tumor is located in an eloquent brain region and resection cannot be performed without compromising normal function.
The combined use of CT and MRi and stereotactic framing devices allows neurosurgeons to perform biopsies with continuous and accurate intraoperative tumor localization. However, we sometimes estimate lower malignancy grading in gliomas with weak edema and no enhanced area on MRi only by performing target selection by stereotactic MRi-guided biopsy. 42) Thus, PeT may be a valuable tool for identifying the most malignant areas in the heterogeneous tumors.
[ 18 F]FDg, the most widespread radiotracer, was shown to be superior for the target selection of stereotactic image-guided biopsy to CT or MRi alone. 43 
Resection planning
in heterogeneous gliomas, resection, including the most malignant part of the tumor, should be performed for correct histopathological evaluation and improvement of prognosis (Fig. 2) . However, only three studies have investigated the value of PeT-guided resection to date. [47] [48] [49] a multimodal navigation system, including several PeT tracers and MRi, has been suggested to be more useful than the conventional navigation system in determining the resection area by providing clearer enhanced lesions of MRi. Resections performed using these systems have resulted in decreased remnant tumor mass and have been associated with improved postsurgical prognosis. Further investigations are needed to assess not only the degree of association between PeT-guided resection and patient outcomes, but also the procedures related to morbidity in comparison with those for MRi-based resection.
Fig. 1 This Figure shows three illustrative cases. The upper panel shows a WHO grade II case (diffuse astrocytoma) (A, B, C, D, E, and F). The middle panel shows a WHO grade III case (anaplastic astrocytoma) (G, H, I, J, K, and L). The lower panel shows a WHO grade IV case (glioblastoma) (M, N, O, P, Q, and R). FLAIR images (A, G, and M), enhanced-T 1 WI (B, H, and N), FDG PET images (C, I, and O), MET PET images (D, J, and P), FLT PET images (E, K, and Q), and FMISO PET images (F, L, and R) are shown. Comparison of T/N or T/B ratios and
Radiation therapy planning
Radiation therapy for gliomas performed on the basis of CT and MRi information has developed and is useful for the local control of gliomas. However, the recurrence site is observed within 2-3 cm of the margin of the original lesion in ~80% of glioma patients. 50) Therefore, the usefulness of PeT-based biological target volume (BTV) for radiation therapy planning has been reported. 51, 52) Particularly for high-grade gliomas, treatment planning based on [
18 F]FeT combined with CT/MRi has also been associated with improved survival in comparison with that based on CT/MRi alone. 50, 53) Therefore, biological treatment planning based on amino acid PeT appears to be very promising.
Because the tumor hypoxic region is highly resistant to radiation therapy, it is very important to evaluate images in the tumor hypoxic region prior to radiation therapy. 54) However, only a few clinical studies have assessed hypoxia-marker uptake and treatment response to radiotherapy.
Assessment of treatment response to chemotherapy
For glioma patients treated with chemotherapy, [
11 C]MeT and [ 18 F]FeT PeT may improve response assessment. The assessment of treatment response to adjuvant temozolomide chemotherapy has been demonstrated using [ 11 C]MeT in patients with recurrent high-grade glioma. 55) Similarly, [ 18 F]FeT PeT has been used to assess the effects of temozolomide chemotherapy and may provide earlier indications of a successful treatment than can standard MRi for this patient group. 56) Since 2013, it has been possible to introduce antiangiogenic drugs, such as bevacizumab, for malignant gliomas in Japan. However, a previous study has shown that the problem of pseudoresponse cannot be solved by the treatment evaluation of images based on the Macdonald criteria alone. 57) For rapidly reducing enhanced lesions after bevacizumab treatment initiation, it would be incorrect to conclude that the response rate is high.
58) The reduction of enhanced lesions in MRi is caused by the rapid normalization of abnormal vascular permeability of BBB, which previously was partially broken. in other words, the reduced enhancement of lesions may not fully reflect the true antitumor activity of antiangiogenic therapy. 59) To overcome the limitations of the Macdonald criteria for antiangiogenic therapy assessment, the Response assessment in Neuro-Oncology (RaNO) group has proposed new recommendations for evaluating responses. 60) For the assessment of treatment response to antiangiogenic therapy, additional metabolic PeT imaging provides an important and valuable addition to standard MRi. [ 18 F]FLT is most useful for evaluating cell proliferation and grading of gliomas. However, [ 18 F]FLT is significantly dependent on BBB permeability and is mainly restricted to contrast-enhancing tumor lesions. Thus, the assessment of treatment response to antiangiogenic therapy based on [
18 F]FLT needs to be carefully interpreted. 61) However, amino acid PeT tracers have been evaluated for the assessment of treatment response to antiangiogenic therapy. 62) Compared with the MRi-based RaNO criteria, [ 18 F] FeT and [
18 F]FDOPa PeT are useful for determining antiangiogenic treatment failure with bevacizumab earlier 63) and have been used to predict a favorable outcome for responders to bevacizumab. 64) a case study showed that [
18 F]FMiSO was useful for the evaluation of the dynamic biological effects of tissue hypoxia on vascular normalization within recurrent high-grade gliomas treated using bevacizumab.
65)
Patient Prognosis
Prognosis prediction
Several prognostic factors have been identified in gliomas, including patient's age, location, and size of the lesion, histology and grade of the tumor, and neurological status. 66) aggressive treatment can cause treatment-related morbidity, whereas, inadequate treatment of progressive lesions may significantly decrease overall survival time. Several imaging modalities need to be used to adjust treatment strategies for the accurate identification of patients with poor or better prognosis because the clinical course of patients with low-or high-grade gliomas varies considerably. widespread [
18 F]FDg PeT uptake has been shown to predict malignant transformation and to correlate with overall survival in a retrospective study. 67) [ 18 F]FeT PeT in combination with MRi has been suggested to enable good prediction of the clinical course and outcome in non-enhanced low-grade gliomas. 68) within the observation period of this study, the best outcome was found for circumscribed lesions without tracer uptake. Conversely, the worst outcome was found in diffuse gliomas with high uptake. a recent study showed an association between volume-based tumor measurements and patient prognosis because [ 11 C]MeT uptake reflected tumor expansion more accurately than did MRi (Figs. 3, 4) . 69) 
Differential Diagnosis of Pseudoprogression
Post-radiation treatment effects can be divided into acute effects (i.e., immediately after or even during radiotherapy), subacute (early-delayed) effects (i.e., pseudoprogression), or late effects, such as radiation necrosis. 72) Pseudoprogression has commonly been defined as a subacute post-treatment reaction with an increased enhanced lesion and edema that mimics tumor progression and recurrence but subsequently stabilizes and regresses without further additional treatment. 73) However, radiation necrosis belongs to the late post-radiation treatment effects category and may appear more than 3 months to several years after radiation therapy, which is later than the typical time period for pseudoprogression; 74) radiation necrosis can also be progressive and irreversible. N ratio, 1.85) (B, blue square) . These PET studies led to a tentative diagnosis of a low-grade glioma with an oligodendroglioma component. This area was selected for tumor sampling using a fusion image of the navigation system (J). Histopathological analysis identified a low-grade astrocytoma (M, hematoxylin-eosin stain; N, Ki-67 labeling index of 2%; scale bar = 100 µm). The correlation between the T/N ratios for MET (C, blue square) or FLT (D, blue square) and Ki-67 labeling index are shown. This tumor was diagnosed as a malignant transformation. Therefore, the PET study was considered to be very useful for treatment monitoring of low-grade gliomas.
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Because radio-chemotherapy with temozolomide is the current standard for glioblastoma treatment, it has led to a sudden increase in contrast-enhancing lesions on MRi that are not related to tumor progression but rather to treatment effects, such as pseudoprogression. Pseudoprogression is typically regarded as a phenomenon of the first 12 weeks after radiotherapy, 75) and this time-dependent definition has been incorporated into the new criteria for RaNO. 60 ) However, it is not possible to distinguish tumor recurrence and pseudoprogression in conventional MRi. [ 18 F]FeT PeT may be useful for this indication within the short time frame of the first 12 weeks after radio-chemotherapy with temozolomide 76) because the sensitivity and specificity of [ 18 F]FeT have been found to be >90% for differentiating pseudoprogression from tumor recurrence in glioblastoma patients. 77 
Conclusion
PeT is a non-invasive molecular imaging examination method that enables measurement of metabolic and molecular processes. although information assessed using MRi will remain essential in glioma management, several studies using the PeT tracers ([ 18 
